by Clinical Neuropsychologist Online | Tuesday, July 21, 2026 | Dementia
Abstract INTRODUCTION Declining nicotinamide adenine dinucleotide (NAD+) may elevate risk of Alzheimer’s disease. METHODS We conducted a 12-week double-blind, randomized, placebo-controlled pilot study to evaluate the safety, tolerability, and preliminary...
by Clinical Neuropsychologist Online | Tuesday, July 21, 2026 | Paediatric Neuropsychology
. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | July 21, 2026 Neuro-Paediatric Previous Page
by Clinical Neuropsychologist Online | Tuesday, July 21, 2026 | Neuropsychology (general)
. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | July 21, 2026 Neuro-General Previous Page
by Clinical Neuropsychologist Online | Monday, July 20, 2026 | Dementia
Abstract INTRODUCTION Although cerebrospinal fluid (CSF) biomarkers reflect neurodegeneration in Alzheimer’s disease (AD), it remains unclear whether these biomarkers track neurodegeneration in early-onset Alzheimer’s disease (EOAD). METHODS In 80 EOAD...
by Clinical Neuropsychologist Online | Monday, July 20, 2026 | Dementia
Abstract People with dementia are at increased risk of hospitalization compared to individuals without dementia, yet the efficacy of psychosocial and healthcare interventions in reducing hospitalization is unclear. We conducted an umbrella review examining the effects...
